Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1906 to 1920 of 2026 results for nice guidelines

  1. Radiation dose monitoring software for medical imaging with ionising radiation (MIB127)

    NICE has developed a medtech innovation briefing (MIB) on radiation dose monitoring software for medical imaging with ionising radiation .

    Medtech innovation briefing
    Published
    31 October 2017

  2. Tests to help assess risk of acute kidney injury for people being considered for critical care admission (ARCHITECT and Alinity i Urine NGAL assays, BioPorto NGAL test and NephroCheck test) (HTG544)

    Evidence-based recommendations on tests to help assess risk of acute kidney injury for people being considered for critical care admission. The tests are the ARCHITECT and ALINITY i Urine NGAL assays, BioPorto NGAL test and NephroCheck test.

    HealthTech guidance
    Published
    17 June 2020
    View recommendations

    Sections for HTG544

  3. Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (TA577)

    Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive cutaneous T-cell lymphoma in adults.

    Technology appraisal guidance
    Published
    24 April 2019
    View recommendations

    Sections for TA577

  4. Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over (HST33)

    Evidence-based recommendations on leniolisib (Joenja) for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over.

    Highly specialised technologies guidance
    Published
    23 April 2025

    Sections for HST33

  5. Testing strategies for Lynch syndrome in people with endometrial cancer (HTG557)

    Evidence-based recommendations on testing strategies for Lynch syndrome for people with endometrial cancer.

    HealthTech guidance
    Published
    28 October 2020
    View recommendations

    Sections for HTG557

  6. Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over (TA1044)

    Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for treating severe sickle cell disease in people 12 years and over.

    Technology appraisal guidance
    Published
    26 February 2025
    View recommendations

    Sections for TA1044

  7. Nirmatrelvir plus ritonavir and tocilizumab for treating COVID-19 (TA878)

    Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid) and tocilizumab (RoActemra) for treating COVID-19.

    Technology appraisal guidance
    Last updated
    26 February 2026
    View recommendations

    Sections for TA878

  8. Suburethral synthetic sling insertion for stress urinary incontinence in men (IPG256)

    This guidance has been withdrawn as the use of this procedure is now covered in NICE guideline CG97. NICE has no plans to carry out further assessment of this procedure under the Interventional procedures programme.

    Withdrawn guidance

  9. Insertion of extraurethral (non-circumferential) retropubic adjustable compression devices for stress urinary incontinence in men (IPG224)

    This guidance has been withdrawn as the use of this procedure is now covered in NICE guideline CG97. NICE has no plans to carry out further assessment of this procedure under the Interventional Procedures Programme.

    Withdrawn guidance

  10. Improving outcomes in haemato-oncology cancer (CSG3)

    This guidance has been updated and replaced by NICE guideline NG47.

    Withdrawn guideline

  11. Smoking: brief interventions and referrals (PH1)

    This guidance has been updated and replaced by NICE guideline NG92.

    Withdrawn guideline

  12. Ulcerative colitis: management (CG166)

    This guidance has been updated and replaced by NICE guideline NG130.

    Withdrawn guideline

  13. Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease (CG67)

    This guidance has been updated and replaced by NICE guideline CG181.

    Withdrawn guideline

  14. Heavy menstrual bleeding: assessment and management (CG44)

    This guidance has been updated and replaced by NICE guideline NG88.

    Withdrawn guideline

  15. Multiple sclerosis: Management of multiple sclerosis in primary and secondary care (CG8)

    This guidance has been updated and replaced by NICE guideline CG186.

    Withdrawn guideline